Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: An instructive case

American Journal of the Medical Sciences

Volumn 335, Issue 2, 2008, Pages 141-144

  Grupper, M ^a,b   Potasman, I ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Fluoroquinolones; Levofloxacin; Tuberculosis

Indexed keywords

ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HUMAN; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 39149093040     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3180a5e8ff     Document Type: Article

References (16)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
2. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003;9:432-7.
3. Carrie AG, Kozyrskyj AL. Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fluoroquinolones. Can J Clin Pharmacol 2006;13:e102-11. Epub 2006 Mar 31.
4. MacDougall C, Guglielmo BJ, Maselli J, et al. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 2005;11:380-4.
5. Karlowsky JA, Thornsberry C, Jones ME, et al, TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003;36:963-70.
6. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
7. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9: 1415-22.
8. Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002;34:1607-12. Epub 2002 May 23.
9. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005;9:1215-9.
10. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903-8.
11. Sterling TR. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 2004;8:1396-400.
12. Ang D, Hsu AA, Tan BH. Fluoroquinolones may delay the diagnosis of tuberculosis. Singapore Med J 2006;47:747-51.
13. Avnon LS, Jotkowitz A, Smoliakov A, et al. Can the routine use of fluoroquinolones for community-acquired pneumonia delay the diagnosis of tuberculosis? A salutary case of diagnostic delay in a pilgrim returning from Mecca. Eur J Intern Med 2006;17:444-6.
14. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2005;20:CD004795.
15. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gaitfloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-12.
16. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-5. Epub 2003 Aug 13.